Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 890758, 16 pages
doi:10.1155/2011/890758
Review Article

Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

Filippo Bellati,1,2 Chiara Napoletano,2 Maria Luisa Gasparri,1 Valeria Visconti,2 Ilaria Grazia Zizzari,2 Ilary Ruscito,1 Jlenia Caccetta,1 Aurelia Rughetti,2 Pierluigi Benedetti-Panici,1 and Marianna Nuti2

1Department of Gynecology and Obstetrics, “Sapienza” University of Rome, Italy
2Department of Experimental Medicine, “Sapienza” University of Rome, Italy

Received 2 July 2011; Revised 4 October 2011; Accepted 3 November 2011

Academic Editor: Enrico Maggi

Copyright © 2011 Filippo Bellati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. K. Oldham and R. O. Dillman, “Monoclonal antibodies in cancer therapy: 25 years of progress,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1774–1777, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. L. M. Nadler, P. Stashenko, R. Hardy, et al., “Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen,” Cancer Research, vol. 40, no. 9, pp. 3147–3154, 1980. View at Scopus
  3. J. R. Thistlethwaite Jr, B. W. Haag, A. O. Gaber et al., “The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine,” Transplantation Proceedings, vol. 19, no. 3, pp. 1901–1904, 1987. View at Scopus
  4. N. L. Spector and K. L. Blackwell, “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5838–5847, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. Ranieri, R. Patruno, E. Ruggieri, S. Montemurro, P. Valerio, and D. Ribatti, “Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic,” Current Medicinal Chemistry, vol. 13, no. 16, pp. 1845–1857, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Linke, A. Klein, and D. Seimetz, “Catumaxomab: clinical development and future directions,” mAbs, vol. 2, no. 2, pp. 129–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. Paley, K. A. Staskus, K. Gebhard et al., “Vascular endothelial growth factor expression in early stage ovarian carcinoma,” Cancer, vol. 80, no. 1, pp. 98–106, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. S. K. Kassim, E. M. El-Salahy, S. T. Fayed et al., “Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients,” Clinical Biochemistry, vol. 37, no. 5, pp. 363–369, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. B. C. Cooper, J. M. Ritchie, C. L. Broghammer et al., “Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer,” Clinical Cancer Research, vol. 8, no. 10, pp. 3193–3197, 2002. View at Scopus
  10. L. Li, L. Wang, W. Zhang et al., “Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer,” Anticancer Research, vol. 24, no. 3, pp. 1973–1979, 2004. View at Scopus
  11. L. A. Hefler, R. Zeillinger, C. Grimm et al., “Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer,” Gynecologic Oncology, vol. 103, no. 2, pp. 512–517, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S. Kuemmel, A. Thomas, S. Landt et al., “Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer,” Anticancer Research, vol. 29, no. 2, pp. 641–645, 2009. View at Scopus
  13. L. M. Randall, B. J. Monk, K. M. Darcy et al., “Markers of angiogenesis in high-risk, early-stage cervical cancer: a gynecologic oncology group study,” Gynecologic Oncology, vol. 112, no. 3, pp. 583–589, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. K. Jain, “Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy,” Nature Medicine, vol. 7, no. 9, pp. 987–989, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Koch, S. Tugues, X. Li, et al., “Signal transduction by vascular endothelial growth factor receptors,” Biochemical Journal, vol. 437, no. 2, pp. 169–183, 2011.
  17. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. Reck, J. von Pawel, P. Zatloukal et al., “Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1227–1234, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. F. Bellati, C. Napoletano, M. L. Gasparri, et al., “Current knowledge and future avenues of bevacizumab in gynecological neoplasms,” Critical Reviews in Oncology Hematology. In press.
  21. B. J. Monk, D. C. Choi, G. Pugmire, and R. A. Burger, “Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer,” Gynecologic Oncology, vol. 96, no. 3, pp. 902–905, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. J. D. Wright, A. Hagemann, J. S. Rader et al., “Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis,” Cancer, vol. 107, no. 1, pp. 83–89, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. E. Cohn, S. Valmadre, K. E. Resnick, L. A. Eaton, L. J. Copeland, and J. M. Fowler, “Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer,” Gynecologic Oncology, vol. 102, no. 2, pp. 134–139, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky, “Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5165–5167, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. J. C. Chura, K. van Iseghem, L. S. Downs Jr, L. F. Carson, and P. L. Judson, “Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer,” Gynecologic Oncology, vol. 107, no. 2, pp. 326–330, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. F. Simpkins, J. L. Belinson, and P. G. Rose, “Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening,” Gynecologic Oncology, vol. 107, no. 1, pp. 118–123, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. A. A. Garcia, H. Hirte, G. Fleming et al., “Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 76–82, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. N. S. Azad, E. M. Posadas, V. E. Kwitkowski et al., “Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3709–3714, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. H. S. Nimeiri, A. M. Oza, R. J. Morgan et al., “Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia,” Gynecologic Oncology, vol. 110, no. 1, pp. 49–55, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. J. D. Hurt, D. L. Richardson, L. G. Seamon et al., “Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer,” Gynecologic Oncology, vol. 115, no. 3, pp. 396–400, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. T. M. Numnum, R. P. Rocconi, J. Whitworth, and M. N. Barnes, “The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma,” Gynecologic Oncology, vol. 102, no. 3, pp. 425–428, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. N. Arora, D. Tewari, C. Cowan, B. Saffari, B. J. Monk, and R. A. Burger, “Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma,” International Journal of Gynecological Cancer, vol. 18, no. 2, pp. 369–372, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. C. A. Hamilton, G. L. Maxwell, M. R. Chernofsky, S. A. Bernstein, J. H. Farley, and G. S. Rose, “Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer,” Gynecologic Oncology, vol. 111, no. 3, pp. 530–532, 2008. View at Publisher · View at Google Scholar · View at PubMed
  34. J. P. Kesterson, P. Mhawech-Fauceglia, and S. Lele, “The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report,” Gynecologic Oncology, vol. 111, no. 3, pp. 527–529, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. F. Bellati, C. Napoletano, I. Ruscito et al., “Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review,” Investigational New Drugs, vol. 28, no. 6, pp. 887–894, 2010. View at Publisher · View at Google Scholar · View at PubMed
  36. C. Napoletano, F. Bellati, R. Landi et al., “Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression,” Journal of Cellular and Molecular Medicine, vol. 14, no. 12, pp. 2748–2759, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. http://www.cancer.gov/ (ID protocol number: NCT00262847).
  38. http://www.cancer.gov/ (ID protocol number: NCT00483782).
  39. http://www.cancer.gov/ (ID protocol number: NCT00976911).
  40. http://www.cancer.gov/ (ID protocol number: NCT00565851).
  41. http://www.cancer.gov (ID protocol number: NCT00434642).
  42. J. Mendelsohn and J. Baselga, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2787–2799, 2003. View at Publisher · View at Google Scholar · View at PubMed
  43. D. J. Slamon, G. M. Clark, S. G. Wong, et al., “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987.
  44. D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989.
  45. J. P. Delord, C. Allal, M. Canal et al., “Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma,” Annals of Oncology, vol. 16, no. 12, pp. 1889–1897, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. M. Fujimura, N. Katsumata, H. Tsuda et al., “HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab,” Japanese Journal of Cancer Research, vol. 93, no. 11, pp. 1250–1257, 2002.
  47. A. H. Boekhout, J. H. Beijnen, and J. H. Schellens, “Trastuzumab,” Oncologist, vol. 16, no. 6, pp. 800–810, 2011.
  48. F. Bellati, C. Napoletano, I. Ruscito, M. Liberati, P. B. Panici, and M. Nuti, “Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy,” Journal of Clinical Oncology, vol. 28, no. 21, pp. e369–e370, 2010. View at Publisher · View at Google Scholar · View at PubMed
  49. M. Nuti, F. Bellati, V. Visconti, et al., “Immune effects of Trastuzumab,” Journal of Cancer, vol. 2, pp. 317–323, 2011.
  50. M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz, “Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 283–290, 2003. View at Publisher · View at Google Scholar
  51. M. C. Franklin, K. D. Carey, F. F. Vajdos, D. J. Leahy, A. M. de Vos, and M. X. Sliwkowski, “Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex,” Cancer Cell, vol. 5, no. 4, pp. 317–328, 2004. View at Publisher · View at Google Scholar
  52. M. A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga, “Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells,” Cancer Research, vol. 61, no. 12, pp. 4744–4749, 2001.
  53. M. S. Gordon, D. Matei, C. J. Aghajanian et al., “Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4324–4332, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. S. Makhija, L. C. Amler, D. Glenn et al., “Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1215–1223, 2010. View at Publisher · View at Google Scholar · View at PubMed
  55. M. Prewett, P. Rockwell, C. Rose, and N. I. Goldstein, “Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin,” International Journal of Oncology, vol. 9, no. 2, pp. 217–224, 1996.
  56. A. A. Secord, J. A. Blessing, D. K. Armstrong et al., “Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study,” Gynecologic Oncology, vol. 108, pp. 493–499, 2008. View at Publisher · View at Google Scholar · View at PubMed
  57. Z. Fan, J. Baselga, H. Masui, and J. Mendelsohn, “Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts,” Cancer Research, vol. 53, no. 19, pp. 4637–4642, 1993.
  58. N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn, “Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model,” Clinical Cancer Research, vol. 1, no. 11, pp. 1311–1318, 1995.
  59. F. L. Sung, T. C. Poon, E. P. Hui et al., “Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells,” In Vivo, vol. 19, no. 1, pp. 237–246, 2005.
  60. D. Balin-Gauthier, J. P. Delord, P. Rochaix et al., “In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR,” Cancer Chemotherapy and Pharmacology, vol. 57, no. 6, pp. 709–718, 2006. View at Publisher · View at Google Scholar · View at PubMed
  61. J. Konner, R. J. Schilder, F. A. DeRosa et al., “A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer,” Gynecologic Oncology, vol. 110, no. 2, pp. 140–145, 2008. View at Publisher · View at Google Scholar · View at PubMed
  62. J. V. Fiorica, J. A. Blessing, L. V. Puneky et al., “A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a gynecologic oncology group study,” Gynecologic Oncology, vol. 115, no. 2, pp. 285–289, 2009. View at Publisher · View at Google Scholar · View at PubMed
  63. A. Burges, P. Wimberger, C. Kümper et al., “Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study,” Clinical Cancer Research, vol. 13, no. 13, pp. 3899–3905, 2007. View at Publisher · View at Google Scholar · View at PubMed
  64. R. Zeidler, J. Mysliwietz, M. Csánady et al., “The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells,” British Journal of Cancer, vol. 83, no. 2, pp. 261–266, 2000.
  65. M. M. Heiss, M. A. Ströhlein, M. Jäger et al., “Immunotherapy of malignant ascites with trifunctional antibodies,” International Journal of Cancer, vol. 117, no. 3, pp. 435–443, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. M. M. Heiss, P. Murawa, P. Koralewski et al., “The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial,” International Journal of Cancer, vol. 127, no. 9, pp. 2209–2221, 2010. View at Publisher · View at Google Scholar · View at PubMed
  67. K. Baumann, J. Pfisterer, P. Wimberger et al., “Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO study group,” Gynecologic Oncology, vol. 123, no. 1, pp. 27–32, 2011. View at Publisher · View at Google Scholar · View at PubMed
  68. K. R. Kalli, “MORAb-003, a fully humanized monoclonal antibody against the folate receptor α, for the potential treatment of epithelial ovarian cancer,” Current Opinion in Investigational Drugs, vol. 8, no. 12, pp. 1067–1073, 2007.
  69. P. M. Smith-Jones, N. Pandit-Taskar, W. Cao et al., “Preclinical radioimmunotargeting of folate receptor α using the monoclonal antibody conjugate DOTA-MORAb-003,” Nuclear Medicine and Biology, vol. 35, no. 3, pp. 343–351, 2008. View at Publisher · View at Google Scholar · View at PubMed
  70. W. A. Spannuth, A. K. Sood, and R. L. Coleman, “Farletuzumab in epithelial ovarian carcinoma,” Expert Opinion on Biological Therapy, vol. 10, no. 3, pp. 431–437, 2010. View at Publisher · View at Google Scholar · View at PubMed
  71. R. C. Bast Jr, T. L. Klug, E. St John, et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,” New England Journal of Medicine, vol. 309, no. 15, pp. 883–887, 1983.
  72. G. J. Rustin, P. Timmers, A. Nelstrop et al., “Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 45–51, 2006. View at Publisher · View at Google Scholar · View at PubMed
  73. G. J. Rustin, M. Marples, A. E. Nelstrop, M. Mahmoudi, and T. Meyer, “Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels,” Journal of Clinical Oncology, vol. 19, no. 20, pp. 4054–4057, 2001.
  74. V. J. Möbus, R. P. Baum, M. Bolle et al., “Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 189, no. 1, pp. 28–36, 2003. View at Publisher · View at Google Scholar
  75. R. P. Baum, A. A. Noujaim, A. Nanci et al., “Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13,” Hybridoma, vol. 12, no. 5, pp. 583–589, 1993.
  76. B. C. Schultes, R. P. Baum, A. Niesen, A. A. Noujaim, and R. Madiyalakan, “Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1),” Cancer Immunology Immunotherapy, vol. 46, no. 4, pp. 201–212, 1998. View at Publisher · View at Google Scholar
  77. A. A. Noujaim, B. C. Schultes, R. P. Baum, and R. Madiyalakan, “Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13—evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo,” Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 3, pp. 187–203, 2001.
  78. A. N. Gordon, B. C. Schultes, H. Gallion et al., “CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients,” Gynecologic Oncology, vol. 94, no. 2, pp. 340–351, 2004. View at Publisher · View at Google Scholar · View at PubMed
  79. J. S. Berek, P. T. Taylor, A. Gordon et al., “Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer,” Journal of Clinical Oncology, vol. 22, no. 17, pp. 3507–3516, 2004. View at Publisher · View at Google Scholar · View at PubMed
  80. T. G. Ehlen, P. J. Hoskins, D. Miller et al., “A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer,” International Journal of Gynecological Cancer, vol. 15, no. 6, pp. 1023–1034, 2005. View at Publisher · View at Google Scholar · View at PubMed
  81. J. S. Berek, P. T. Taylor, C. F. Nicodemus, et al., “CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer,” Journal of Immunotherapy, vol. 31, no. 2, pp. 207–214, 2008. View at Publisher · View at Google Scholar · View at PubMed
  82. J. Berek, P. Taylor, W. McGuire, L. M. Smith, B. Schultes, and C. F. Nicodemus, “Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 418–425, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. X. F. Hu, E. Yang, J. Li, and P. X. Xing, “MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma,” Expert Review of Anticancer Therapy, vol. 6, no. 8, pp. 1261–1271, 2006. View at Publisher · View at Google Scholar · View at PubMed
  84. J. J. Rahn, L. Dabbagh, M. Pasdar, and J. C. Hugh, “The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature,” Cancer, vol. 91, no. 11, pp. 1973–1982, 2001. View at Publisher · View at Google Scholar
  85. L. F. Pemberton, A. Rughetti, J. Taylor-Papadimitriou, and S. J. Gendler, “The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells,” Journal of Biological Chemistry, vol. 271, no. 4, pp. 2332–2340, 1996. View at Publisher · View at Google Scholar
  86. A. Rughetti, V. Turchi, C. A. Ghetti et al., “Human B-cell immune response to the polymorphic epithelial mucin,” Cancer Research, vol. 52, no. 11, pp. 2457–2459, 1993.
  87. R. E. Beatson, J. Taylor-Papadimitriou, and J. M. Burchell, “MUC1 immunotherapy,” Immunotherapy, vol. 2, no. 3, pp. 305–327, 2010. View at Publisher · View at Google Scholar · View at PubMed
  88. J. S. Stewart, V. Hird, D. Snook et al., “Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer,” Journal of Clinical Oncology, vol. 8, no. 12, pp. 1941–1950, 1990.
  89. A. Maraveyas, P. Mason, H. E. Lambert, et al., “Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis,” Oncology Reports, vol. 5, no. 1, pp. 223–226, 2001.
  90. A. A. Epenetos, V. Hird, H. Lambert, P. Mason, and C. Coulter, “Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy,” International Journal of Gynecological Cancer, vol. 10, no. 1, pp. 44–46, 2000. View at Publisher · View at Google Scholar
  91. S. Nicholson, C. C. Bomphray, H. Thomas et al., “A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer,” Cancer Immunology, Immunotherapy, vol. 53, no. 9, pp. 809–816, 2004.
  92. R. H. Verheijen, L. F. Massuger, B. B. Benigno et al., “Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 571–578, 2006. View at Publisher · View at Google Scholar · View at PubMed
  93. A. L. Oei, F. C. Sweep, C. M. Thomas, O. C. Boerman, and L. F. A. G. Massuger, “The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review),” International Journal of Oncology, vol. 32, no. 6, pp. 1145–1157, 2008. View at Publisher · View at Google Scholar
  94. A. L. Oei, M. Moreno, R. H. Verheijen et al., “Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer,” International Journal of Cancer, vol. 123, no. 8, pp. 1848–1853, 2008. View at Publisher · View at Google Scholar · View at PubMed
  95. http://www.antisoma.com/.
  96. F. S. Hodi, D. A. Oble, J. Drappatz et al., “CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS,” Nature Clinical Practice Oncology, vol. 5, no. 9, pp. 557–561, 2008. View at Publisher · View at Google Scholar · View at PubMed
  97. S. Kuemmel, A. Thomas, S. Landt et al., “Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer,” Anticancer Research, vol. 29, no. 2, pp. 641–645, 2009.
  98. L. M. Randall, B. J. Monk, K. M. Darcy et al., “Markers of angiogenesis in high-risk, early-stage cervical cancer: a gynecologic oncology group study,” Gynecologic Oncology, vol. 112, no. 3, pp. 583–589, 2009. View at Publisher · View at Google Scholar · View at PubMed
  99. W. F. Cheng, C. A. Chen, C. N. Lee, L. H. Wei, F. J. Hsieh, and C. Y. Hsieh, “Vascular endothelial growth factor and prognosis of cervical carcinoma,” Obstetrics and Gynecology, vol. 96, no. 5, pp. 721–726, 2000. View at Publisher · View at Google Scholar
  100. J. A. Loncaster, R. A. Cooper, J. P. Logue, S. E. Davidson, R. D. Hunter, and C. M. L. West, “Vascular endothelial growth factor (VEGF) expression is a prognostic faster for radiotherapy outcome in advanced carcinoma of the cervix,” British Journal of Cancer, vol. 83, no. 5, pp. 620–625, 2000.
  101. B. J. Monk, M. W. Sill, R. A. Burger, H. J. Gray, T. E. Buekers, and L. D. Roman, “Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1069–1074, 2009. View at Publisher · View at Google Scholar · View at PubMed
  102. J. D. Wright, A. Hagemann, J. S. Rader et al., “Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis,” Cancer, vol. 107, no. 1, pp. 83–89, 2006. View at Publisher · View at Google Scholar · View at PubMed
  103. http://www.cancer.gov/ (ID protocol number: NCT00803062).
  104. F. Bellati, M. L. Gasparri, and P. B. Panici, “Is there a real standard for stage Iva cervical cancer?” Gynecologic Oncology, vol. 123, no. 1, pp. 174–175, 2011.
  105. P. B. Panici, F. Bellati, M. Pastore et al., “An update in neoadjuvant chemotherapy in cervical cancer,” Gynecologic Oncology, vol. 107, supplement 1, pp. S20–S22, 2007. View at Publisher · View at Google Scholar · View at PubMed
  106. P. B. Panici, F. Bellati, N. Manci et al., “Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer,” Annals of Surgical Oncology, vol. 14, no. 9, pp. 2643–2648, 2007. View at Publisher · View at Google Scholar · View at PubMed
  107. R. J. Hale, C. H. Buckley, W. J. Gullick, H. Fox, J. Williams, and F. L. Wilcox, “Prognostic value of epidermal growth factor receptor expression in cervical carcinoma,” Journal of Clinical Pathology, vol. 46, no. 2, pp. 149–153, 1993.
  108. A. M. Kersemaekers, G. J. Fleuren, G. G. Kenter et al., “Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis,” Clinical Cancer Research, vol. 5, no. 3, pp. 577–586, 1999.
  109. G. E. Kim, Y. B. Kim, N. H. Cho et al., “Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival,” Clinical Cancer Research, vol. 10, no. 4, pp. 1366–1374, 2004. View at Publisher · View at Google Scholar
  110. M. J. Oh, J. H. Choi, I. H. Kim et al., “Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma,” Clinical Cancer Research, vol. 6, no. 12, pp. 4760–4763, 2000.
  111. D. Pfeiffer, B. Stellwag, A. Pfeiffer, P. Borlinghaus, W. Mjeier, and P. Scheidel, “Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix,” Gynecologic Oncology, vol. 33, no. 2, pp. 146–150, 1989.
  112. J. Bellone, L. Norton, H. Masui et al., “Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease,” Gynecologic Oncology, vol. 106, no. 3, pp. 513–520, 2007. View at Publisher · View at Google Scholar · View at PubMed
  113. K. Y. Chung, J. Shia, N. E. Kemeny et al., “Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1803–1810, 2005. View at Publisher · View at Google Scholar · View at PubMed
  114. S. Bellone, G. Frera, G. Landolfi et al., “Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease,” Gynecologic Oncology, vol. 106, no. 3, pp. 513–520, 2007. View at Publisher · View at Google Scholar · View at PubMed
  115. D. D. Meira, V. H. de Almeida, J. S. Mororó et al., “Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells,” British Journal of Cancer, vol. 101, no. 5, pp. 782–791, 2009. View at Publisher · View at Google Scholar · View at PubMed
  116. A. D. Santin, M. W. Sill, D. S. McMeekin et al., “Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study,” Gynecologic Oncology, vol. 122, no. 3, pp. 495–500, 2011. View at Publisher · View at Google Scholar · View at PubMed
  117. J. E. Kurtz, A. C. Hardy-Bessard, M. Deslandres et al., “Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial,” Gynecologic Oncology, vol. 113, no. 1, pp. 16–20, 2009. View at Publisher · View at Google Scholar · View at PubMed
  118. L. Hertlein, M. Lenhard, A. Kirschenhofer et al., “Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients,” Archives of Gynecology and Obstetrics, vol. 283, no. 1, pp. 109–113, 2011. View at Publisher · View at Google Scholar · View at PubMed
  119. J. Farley, M. W. Sill, M. Birrer et al., “Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a gynecologic oncology group study,” Gynecologic Oncology, vol. 121, no. 2, pp. 303–308, 2011. View at Publisher · View at Google Scholar · View at PubMed
  120. C. Aghajanian, M. W. Sill, K. Darcy, et al., “A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group (GOG) study—ASCO,” Journal of Clinical Oncology, vol. 27, p. 15s, 2009.
  121. J. D. Wright, M. A. Powell, J. S. Rader, D. G. Mutch, and R. K. Gibb, “Bevacizumab therapy in patients with recurrent uterine neoplasms,” Anticancer Research, vol. 27, no. 5, pp. 3525–3528, 2007.
  122. N. Katsumata, M. Yasuda, F. Takahashi et al., “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 374, no. 9698, pp. 1331–1338, 2009. View at Publisher · View at Google Scholar
  123. D. M. O'Malley, D. L. Richardson, P. S. Rheaume et al., “Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer,” Gynecologic Oncology, vol. 121, no. 2, pp. 269–272, 2011. View at Publisher · View at Google Scholar · View at PubMed
  124. M. Markman, “Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer,” Gynecologic Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed
  125. D. Lau, L. Guo, D. Gandara, L. J. T. Young, and L. Xue, “Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?” Anti-Cancer Drugs, vol. 15, no. 9, pp. 871–875, 2004. View at Publisher · View at Google Scholar
  126. I. Vandenput, I. V. Bempt, K. Leunen et al., “Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports,” Gynecologic and Obstetric Investigation, vol. 67, no. 1, pp. 46–48, 2009. View at Publisher · View at Google Scholar · View at PubMed